SecBot SecBot

KZIA

KAZIA THERAPEUTICS LTD
Nasdaq· Pharmaceutical Preparations· Inc. C3· CIK 0001075880 Biotech & Drug Discovery
$7.87 +0.06 (+0.77%)
Oct 26 4:00 PM ET · prev $7.81
Market cap
$125.5M
Micro cap
Consensus
Buy
92% Buy or better · 12 analysts
Median target
🔒 Subscribers only
1 year
+7.8%
from $7.30 · Oct 27
30 days
−18.0%
from $9.60
52-week range
$5.00–16.90
−53% from high · low Jan 2
Avg volume 20D
214.0K
Oct 14 spike 825.3K
Short interest
1.17M
≈7.5% of shares · +52.6%
Days to cover
3.8
at average volume
Insider net
$0
no open-market trades · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
16
analyzed by SecBot
SecBot read MIXED 9 reports · 90 days
Balance 4 bearish · 3 bullish · 2 neutral oldest → newest, height = score
Avg score ·High conf. 8/9
Strongest BULLISH Dauntless Investment Group, LLC filed a Schedule 13G/A disclosing a new 5.42% passive stake in Kazia…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.

  • InstitutionsBULLISH

    Q2 2026: 5 added (0 new), 2 trimmed or exited.

  • AnalystsBULLISH

    11 of 12 rate it Buy or better.

  • Short sellersBUILDING

    Short interest +52.6% to 1.17M shares. 3.8 days to cover, ≈7.5% of shares.

  • TrendDOWNTREND

    26% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
UBS Group AGDOUBLED81,090$1.1M
BARCLAYS PLCDOUBLED56,999$802.5K
MORGAN STANLEYDOUBLED46,606$656.2K
BNP PARIBAS FINANCIAL MARKETSDOUBLED30,090$423.7K
RAYMOND JAMES FINANCIAL INCADD22,599$318.2K
Sequoia Financial Advisors, LLCTRIM20,003$281.6K
OSAIC HOLDINGS, INC.NEAR_EXIT10$140.00
UBS Group AGDOUBLED13,934$103.7K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

12 analysts
Buy 92% rate it Buy or better
Strong Buy3Buy8Hold1Sell0Strong Sell0

Fresh Price Targets

Analyst price targets updated within the last 24 hours are for subscribers only.

Subscribe for Full Access
Recent actions
DateFirmActionRating
Oct 21, 2026Guggenheim
INITIATE
INITIATEBuy
Oct 20, 2026Leerink Partners
INITIATE
INITIATEOutperform
Sep 10, 2026BTIG
REITERATE
REITERATEBuy
Sep 1, 2026BTIG
MAINTAIN
MAINTAINBuy
Aug 13, 2026Canaccord Genuity
INITIATE
INITIATEBuy
Jul 15, 2026BTIG
REITERATE
REITERATEBuy

Insider ledger

Form 4
$0
open-market buys or sells · 12 mo
DateInsiderTypeValue
Jun 19, 2026
Rao Sudha
Chief Scientific Officer
AWARD250,000 sh
Jun 19, 2026
Levine James E.
Chief Financial Officer
AWARD200,000 sh
Jan 8, 2026
APPLE ROBERT F
Director
AWARD75,000 sh
Jan 8, 2026
Friend John E. II
Chief Executive Officer
AWARD500,000 sh
Jan 8, 2026
Friend John E. II
Chief Executive Officer
AWARD150,000 sh
Jan 8, 2026
Bonacorda Jeffrey
VP, Finance and Controller
AWARD150,000 sh
Jan 8, 2026
Davidson Ebru
Director
AWARD100,000 sh
Jan 8, 2026
Cain David
Director, CMC
AWARD100,000 sh

Earnings setup

Estimates
PeriodEPS est.Range30D rev.Revenue
Current Q———$0.00
Next Q———$0.00
Current FY-$0.01-$0.02–-$0.01+25.0%$926.4K
Next FY-$0.01-$0.02–-$0.01+31.6%$458.6K

Short side

FINRA· Sep 30, 2026
1,174,188
shares short
+52.6%
vs prior settlement
3.8
days to cover
≈7.5%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 2, 2026 SEC
Dauntless Investment Group, LLC filed a Schedule 13G/A disclosing a new 5.42% passive stake in Kazia Therapeutics…
SC 13G/A — Impact 5/10
Sep 30, 2026 Short interest report
Short Interest: KZIA up 53% to 1.2M shares
Settlement 2026-09-30 | Days to cover: 3.77 | ≈7.55% of shares outstanding (est.)
Sep 22, 2026 SEC
Kazia Therapeutics announced that its licensee Sovargen dosed the first patient in a Phase 1b/2a trial of paxalisib…
6-K — Impact 5/10
Sep 1, 2026 SEC
Kazia Therapeutics announced preclinical data for paxalisib in two new large-market indications: MSS/pMMR colorectal…
6-K — Impact 6/10
Aug 31, 2026 Press
Kazia Therapeutics closed an oversubscribed, tranched public offering generating approximately $40 million in upfront…
Impact 6/10
Jun 30, 2026 Inst.
UBS Group AG — DOUBLED
81,090 shares ($1.1M)
Jun 30, 2026 Inst.
BARCLAYS PLC — DOUBLED
56,999 shares ($802.5K)
Jun 19, 2026 Insider
Rao Sudha was granted 250,000 shares
Chief Scientific Officer
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Sep 30, 2026
Short interest
Short Interest: KZIA up 53% to 1.2M shares
Settlement 2026-09-30 | Days to cover: 3.77 | ≈7.55% of shares outstanding (est.)
Sep 25, 2026
Clinical Trial
Paxalisib With a High Fat, Low Carb Diet and Metformin for Glioblastoma
Phase 2 · COMPLETED
Sep 22, 2026
Press release
Kazia Therapeutics Announces Sovargen Co. Doses First Patient in Phase 1b/2a Trial of Paxalisib for Rare Seizure Disorders
Clinical Milestone Expands Development of Paxalisib Beyond Oncology and Triggers $2 Million Payment to Kazia SYDNEY, Sept. 22, 2026 /PRNewswire/…
Sep 9, 2026
Press release
Kazia Therapeutics Announces First Patient Dosed in PNOC035 Clinical Study Evaluating Paxalisib for Recurrent Pediatric AT/RT Brain Cancer
Multicenter study to evaluate paxalisib plus gemcitabine for children and young adults with recurrent or progressive AT/RT, where no approved…
Aug 31, 2026
Offering
Kazia Therapeutics Limited Announces Oversubscribed Closing of Up to $120 Million Public Offering
Company to host a corporate update call Tuesday, September 1st at 8:00am ET SYDNEY, Aug. 31, 2026 /PRNewswire/ -- Kazia Therapeutics Limited…

SecBot reports

16 filings · 1 press release · 8 bullish · 3 bearish · 1 mixed · 4 neutral
All KZIA filing & press-release reports (17)